# A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

> **NCT06139406** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 70 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** JNJ-87801493
- **DRUG:** JNJ-80948543
- **DRUG:** JNJ-75348780

## Key facts

- **NCT ID:** NCT06139406
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06139406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06139406, "A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06139406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*